{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["379"],"submitter":["Ferdinands JM"],"funding":["National Center for Immunization and Respiratory Diseases"],"pubmed_abstract":["<h4>Objective</h4>To estimate the effectiveness of mRNA vaccines against moderate and severe covid-19 in adults by time since second, third, or fourth doses, and by age and immunocompromised status.<h4>Design</h4>Test negative case-control study.<h4>Setting</h4>Hospitals, emergency departments, and urgent care clinics in 10 US states, 17 January 2021 to 12 July 2022.<h4>Participants</h4>893 461 adults (≥18 years) admitted to one of 261 hospitals or to one of 272 emergency department or 119 urgent care centers for covid-like illness tested for SARS-CoV-2.<h4>Main outcome measures</h4>The main outcome was waning of vaccine effectiveness with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine during the omicron and delta periods, and the period before delta was dominant using logistic "],"journal":["BMJ (Clinical research ed.)"],"pagination":["e072141"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9527398"],"repository":["biostudies-literature"],"pubmed_title":["Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study."],"pmcid":["PMC9527398"],"pubmed_authors":["Rao S","Dixon BE","Griggs EP","Link-Gelles R","Williams J","Embi PJ","Naleway AL","Dascomb K","Murthy K","Irving SA","Stenehjem E","Ong TC","Goddard K","Gaglani M","Patel P","Raiyani C","Thompson MG","Natarajan K","Bozio CH","Ferdinands JM","Grannis SJ","Liao IC","Arndorfer J","Dickerson M","McEvoy C","Grisel N","Barron MA","Blanton L","Lewis N","Fadel WF","Valvi NR","Yang DH","Klein NP","Mitchell PK","Fireman B","Han J","Reese SE","DeSilva MB","Zerbo O","Birch R"],"additional_accession":[]},"is_claimable":false,"name":"Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study.","description":"<h4>Objective</h4>To estimate the effectiveness of mRNA vaccines against moderate and severe covid-19 in adults by time since second, third, or fourth doses, and by age and immunocompromised status.<h4>Design</h4>Test negative case-control study.<h4>Setting</h4>Hospitals, emergency departments, and urgent care clinics in 10 US states, 17 January 2021 to 12 July 2022.<h4>Participants</h4>893 461 adults (≥18 years) admitted to one of 261 hospitals or to one of 272 emergency department or 119 urgent care centers for covid-like illness tested for SARS-CoV-2.<h4>Main outcome measures</h4>The main outcome was waning of vaccine effectiveness with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine during the omicron and delta periods, and the period before delta was dominant using logistic ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-05-29T22:29:43.313Z","creation":"2025-05-29T22:29:43.313Z"},"accession":"S-EPMC9527398","cross_references":{"pubmed":["36191948"],"doi":["10.1136/bmj-2022-072141"]}}